CompanyNRXPNasdaqWilmington, DE

NRX Pharmaceuticals, Inc.

NRx Pharmaceuticals develops NMDA receptor-based therapeutics for central nervous system disorders.

SEC EDGAR ClinicalTrials.gov nrxpharma.com

8-KSep 16Latest SEC filing, period to Sep 15

Aug 17Latest story

August 2026

NRx reports Q2 2026 results, advances ketamine ANDA and DARPA-backed NRX-101 trial

Aug 17Quarterly updateketamine NRX Pharmaceuticals, Inc.